Inhibiting CDK9 disrupts transcriptional processes crucial for cancer cell survival and proliferation while modulating CYP3A4 activity could optimize the pharmacokinetics of chemotherapeutic agents, improving their efficacy. This evidence concerns the gene CYP3A4 and cancer.